SCV-07: Phase IIb data

SciClone discontinued development of SCV-07 to treat HCV after top-line data from an open-label, U.S. Phase IIb trial in 40 non-cirrhotic patients with chronic HCV genotype 1 infection who have relapsed after >=44 weeks of treatment with Pegasys peginterferon alfa-2a and Copegus ribavirin showed that subcutaneous SCV-07 missed the primary endpoint of a 2 log10 copies/mL reduction in HCV viral load from baseline to week 8. On secondary endpoints, 38.5% (5/13) and 44.4% (8/18) of patients receiving 0.1 and 1 mg/kg SCV-07, respectively, achieved a reduction in viral load of >0.5 log10 copies/mL from baseline. Additionally, 3 patients receiving high-dose SCV-07 achieved a viral load reduction of >1 log10 copies/mL from baseline. SCV-07 was well tolerated. ...